Muscle & Nerve · 2016 · 34 citations · 18 references
Life SciencesImmunologyPathologyAutoimmunityClinical ImmunologyImmunopathologyAutoantibodiesAutoimmune Disease PathogenesisAutoimmune Disease PathologyAutoimmune DiseasesHumoral ImmunityMyasthenia GravisAchr Antibody-mediated DiseaseAnti-acetylcholine Receptor AntibodiesAntibodiesComparative Disease Severity
INTRODUCTION: Myasthenia gravis (MG) is a B-cell-mediated autoimmune disease. B-cell-activating factor (BAFF) is a major factor in B-cell development and activation. In this study we investigated serum BAFF levels in MG patients. METHODS: We compared the serum BAFF levels of 20 MG patients with gender-matched healthy controls. We assayed serum concentrations of BAFF and anti-acetylcholine receptor antibody (AChR) titers. RESULTS: Serum BAFF levels of MG patients with AChR antibodies were significantly higher than those of healthy controls. A significant positive correlation was observed between serum BAFF levels and anti-AChR antibody titers. BAFF values did not correlate with disease severity. CONCLUSIONS: BAFF may play a major role in the pathogenesis of MG, and it may provide a potential target for therapy in patients with MG. Muscle Nerve 54: 1030-1033, 2016.
18
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Paul A. Moore, Ornella Belvedere, A. S. ORR et al. · Science · 1999 · 1.1K citations
Synthesis and release of B-lymphocyte stimulator from myeloid cells
Bernardetta Nardelli, Ornella Belvedere, Viktor Roschke et al. · Blood · 2001 · 575 citations · Full text
Lai Guan Ng, Andrew P. R. Sutherland, Rebecca Newton et al. · The Journal of Immunology · 2004 · 494 citations
Life Sciences, Immunology, Pathology +13